Updates

September 30, 2020September 28, 2020
Ankylosing Spondylitis Is Not Your Fault

Some people just don’t “get” chronic illness, and they can be pretty cruel about it — or thoughtless, at the very least. It’s hard ... Read more
September 28, 2020September 28, 2020
Study Supports Efficacy of Cosentyx for Patients in China, Other Countries

Cosentyx (secukinumab) is a safe and effective treatment for ankylosing spondylitis (AS), producing similar results in Chinese patients compared to other ... Read more
September 21, 2020September 21, 2020
Obesity Increases Risk of Worse Overall Health in AS, Study Reports

Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS), and is associated with increased inflammation, disease activity, ... Read more
September 14, 2020September 14, 2020
Cosentyx Effective in Active nr-axSpA, Phase 3 PREVENT Trial Shows

Treatment with Cosentyx (secukinumab) leads to sustained reductions in symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) over one year, according to the ... Read more
September 3, 2020September 3, 2020
Same But Different Photo Contest Celebrates People With Rare Diseases

Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

March 7, 2018March 7, 2018

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

News

Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were particularly noticeable in patients who had never ... Read more

Updates

Ankylosing Spondylitis Is Not Your Fault

Study Supports Efficacy of Cosentyx for Patients in China, Other Countries

Obesity Increases Risk of Worse Overall Health in AS, Study Reports

Cosentyx Effective in Active nr-axSpA, Phase 3 PREVENT Trial Shows

Same But Different Photo Contest Celebrates People With Rare Diseases

Subscribe to our mailing list

AbbVie Seeks FDA, EMA Approvals of Rinvoq for Active AS

Xperiome Platform Aims to Streamline Searches for Rare Diseases, Gain Patient Input

TNF Inhibitors Significantly Slow Bone Damage in AS, Long-term Study Finds

EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US

IL-17 Inhibitors Can Ease Symptoms But Raise Infection Risk, Review Shows

New Streaming Channel Showcases Rare Disease Films

nr-axSpA Given Diagnostic Code on International Classification of Diseases

Year’s Use of Cimzia Can Lead to Sustained Remission, Phase 3b Trial Shows

EU Approves Under-the-skin Remsima Injectable for 5 Autoimmune Disorders

Hulio, Humira Biosimilar, Approved But Not Available Until 2023

CHMP Favors At-home Injection Form of Remsima for Europe

Alexion Charitable Foundation Giving $1.1M to Assist Rare Disease Community During Pandemic

Simponi Effective, Including in Patients Who Tried Other TNF Blockers, Data Show

Cosentyx Approved in US to Treat Active nr-axSpA

Nepexto, Enbrel Biosimilar, Approved to Treat Patients in Europe

Coalition Will Address Racial Disparities in Rare Disease Communities

FDA Approves Taltz for Non-radiographic Axial Spondyloarthritis

UK Study Evaluating COVID-19 Lockdown Effect on Musculoskeletal Health

COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say

Eurordis Urges Expansion of Newborn Screening Initiatives Across Europe

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

Survey Finds Cimzia Prescriptions for nr-axSpA on the Rise in US

Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

Pin It on Pinterest

Ankylosing Spondylitis Is Not Your Fault

Study Supports Efficacy of Cosentyx for Patients in China, Other Countries

Obesity Increases Risk of Worse Overall Health in AS, Study Reports

Cosentyx Effective in Active nr-axSpA, Phase 3 PREVENT Trial Shows

Same But Different Photo Contest Celebrates People With Rare Diseases

Subscribe to our mailing list

AbbVie Seeks FDA, EMA Approvals of Rinvoq for Active AS

Xperiome Platform Aims to Streamline Searches for Rare Diseases, Gain Patient Input

TNF Inhibitors Significantly Slow Bone Damage in AS, Long-term Study Finds

EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US

IL-17 Inhibitors Can Ease Symptoms But Raise Infection Risk, Review Shows

New Streaming Channel Showcases Rare Disease Films

nr-axSpA Given Diagnostic Code on International Classification of Diseases

Year’s Use of Cimzia Can Lead to Sustained Remission, Phase 3b Trial Shows

EU Approves Under-the-skin Remsima Injectable for 5 Autoimmune Disorders

Mindfulness Linked to Reduced Fatigue-associated Disability in Arthritis

Hulio, Humira Biosimilar, Approved But Not Available Until 2023

National Survey Seeks to Assess Full Social, Economic Burdens of Rare Diseases in US

CHMP Favors At-home Injection Form of Remsima for Europe

Alexion Charitable Foundation Giving $1.1M to Assist Rare Disease Community During Pandemic

Simponi Effective, Including in Patients Who Tried Other TNF Blockers, Data Show

Cosentyx Approved in US to Treat Active nr-axSpA

Nepexto, Enbrel Biosimilar, Approved to Treat Patients in Europe

Coalition Will Address Racial Disparities in Rare Disease Communities

FDA Approves Taltz for Non-radiographic Axial Spondyloarthritis

UK Study Evaluating COVID-19 Lockdown Effect on Musculoskeletal Health

COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say

Eurordis Urges Expansion of Newborn Screening Initiatives Across Europe

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

Survey Finds Cimzia Prescriptions for nr-axSpA on the Rise in US

Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

Pin It on Pinterest